Key To How 'Triggering Event' In Cancer Occurs: Researchers Link Hormone To Creation Of Gene Fusion In Prostate Cancer Oct 31, 2009
The diagnostic field of use has been licensed to Gen-Probe Inc. Chinnaiyan also has a sponsored research agreement with Gen-Probe. Gen-Probe has had no role in the design or experimentation of this study, nor has it participated in the writing of the manuscript. (Science Daily)
U.S. to get 30 million doses of swine flu shot Oct 30, 2009
Separately, Gen-Probe Inc. said Thursday the Food and Drug Administration granted emergency approval to its diagnostic test for the 2009 swine flu. The test maker said the FDA approved its Prodesse ProFlu-ST test, which Gen-Probe says can diagnose swine flu in as little as three hours, while tests using throat cultures can take weeks. (MSNBC -- Health)
Local Biotech Firm Buys Flu-Testing Company Oct 14, 2009
Gen-Probe has developed a number of tests for different diseases ranging from HIV to hepatitis C to West Nile virus ... "We think this is a real business with real revenue, real profit. It puts us in the segment of a market we weren't currently playing in" said Gen-Probe Vice President Michael Watts ... Gen-Probe expects the acquisition of Prodesse will mean an additional $15 million in revenues next year. (TheSanDiegoChannel.com, CA)
Waukesha's Prodesse to be bought for $60M Oct 7, 2009
The purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011, Gen-Probe (NASDAQ: GPRO) said in a press release Tuesday ... In connection with the acquisition, Gen-Probe and Prodesse have signed an agreement under which Gen-Probe's sales representatives in the United States, Canada and Europe will begin co-promoting Prodesse's products in mid-October ... "We believe acquiring Prodesse supports our strategic focus on... (Milwaukee Business Journal, WI)
DiagnoCure signs distribution agreement in the UK for its colorectal cancer test Oct 5, 2009
Lab21 is a leading provider of state-of-the-art diagnostics and world class customer service (Canada Newswire)
Quarterly Changes to the NASDAQ Q-50 Index Sep 12, 2009
As a result of the evaluation, the following eight securities will be removed from the Index: Career Education Corporation (Nasdaq: - ), Gentex Corporation (Nasdaq: - ), Gen-Probe Incorporated (Nasdaq: - ), Leap Wireless International, Inc. (Nasdaq: - ), Lincoln Electric Holdings, Inc. (Nasdaq: - ), OSI Pharmaceuticals Inc. (Nasdaq: - ), Patterson-UTI Energy, Inc. (Nasdaq: - ), and VCA Antech, Inc. (Nasdaq: - ). The NASDAQ Q-50 Index is the basis for the PowerShares NXQ Portfolio (Fund) (Nasdaq:... (Primezone Releases)
Gen-Probe to Webcast Four Upcoming Investor Presentations Sep 4, 2009
SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: ) announced today that the Company will present at the following investor conferences ... These presentations are scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at ... Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose... (PR Newswire)
En Banc Federal Circuit to Address Closely Watched Patent Issue Aug 26, 2009
The Federal Circuit's 2002 ruling and dissents in Enzo Biochem Inc. v. Gen-Probe Inc., which upheld the separate written description requirement, highlighted the ongoing debate on the court, Burchfiel said. But the Federal Circuit declined a petition for an en banc rehearing of Enzo. (Law.com)
Some companies left behind in bull's dust Aug 12, 2009
Real solutions for your real estate needs. Choose from the selections below. (USA Today -- Money)
Gen-Probe to Webcast Presentation at the Canaccord Adams 29th Annual Global Growth Conference Aug 4, 2009
SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: ) announced today that the Company will present at the Canaccord Adams 29th Annual Global Growth Conference on Tuesday, August 11, 2009 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The presentation is scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at ... Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of... (PR Newswire)
Newly Discovered Gene Fusion May Lead To Improved Prostate Cancer Diagnosis Jul 28, 2009
Gen-Probe, a biotechnology diagnostics company, has licensed this technology and is currently working with Dr. Rubin, and his collaborator Dr. Arul Chinnaiyan at the University of Michigan, to develop urine tests to screen for gene fusions as a means of improving upon the current standard PSA test. Dr. Rubin, working in collaboration with Dr. Chinnaiyan's group at the University of Michigan, previously described the discovery of the TMPRSS2-ERG fusion found in 45 percent of prostate cancers. (Science Daily)
AIM: Management seeks regulatory changes Jul 2, 2009
80m) and Tepnel Life Sciences, a molecular diagnostics and pharmaceutical (acquired by NASDAQ-listed Gen-Probe in April for GBP 93m). Separately, the AIM has seen increasing competition from the likes of Plus Market and even its parent company LSE.. (FT.com -- Markets)
Stocks Rise In Light Trade May 3, 2009
eIBD Investor's Business Daily Digital Edition. Access recent eIBD issues easily. (Investors Business Daily)
New Highly Sensitive Method May Offer Early Detection Of Dengue Virus Apr 28, 2009
The researchers are from Gen-Probe Incorporated, San Diego, California and the Centers for Disease Control and Prevention, San Juan, Puerto Rico and Fort Collins, Colorado. Dengue virus (DENV) is currently recognized as the most widely spread mosquito-borne virus. (Science Daily)
DiagnoCure to Host Q1 2009 Earnings Conference Call and Webcast Mar 3, 2009
The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. (Canada Newswire)
Tests Might Diagnose, Predict Prostate Cancer Feb 26, 2009
"Current methods for diagnosing prostate cancer -- PSA (prostate-specific antigen) and digital rectal exam -- have low specificity," lead researcher Jack Groskopf, a senior research scientist for Gen-Probe Inc., in San Diego, said during a Tuesday teleconference. "As a result, the majority of prostate biopsies are negative, and you could argue that we are doing too many biopsies.". (MEDLINEplus)
